The Roche Group launched two new medicines in 2024 and expanded its portfolio with the acquisition in November of Poseida Therapeutics Inc, a developer of allogeneic cell therapies. The deal, valued at $1.5 billion, capped a year of expansion for the Swiss company which grew sales by 3% in Swiss francs and by 7% at constant exchange rates. This was despite the loss of exclusivity for six legacy medicines which saw a sales decline of CHF 1 billion.
